[{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"EQRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Aumolertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ EQRx","highestDevelopmentStatusID":"15","companyTruncated":"Hansoh Pharma \/ EQRx"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aumolertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HS-20093","moa":"Topoisomerase","graph1":"Oncology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansoh Pharma \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ GSK"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"HS-10535","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Hansoh Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HS-20089","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansoh Pharma \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ GSK"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Merigolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HS-20093","moa":"Topoisomerase","graph1":"Oncology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Hansoh Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : HS-10518 (merigolix) is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which is being investigated for improvement of pregnancy rate per cycle.

                          Product Name : HS-10518

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 20, 2025

                          Lead Product(s) : Merigolix

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Under the agreement, Hansoh has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.

                          Product Name : HS-10535

                          Product Type : Other Small Molecule

                          Upfront Cash : $112.0 million

                          December 18, 2024

                          Lead Product(s) : HS-10535

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Preclinical

                          Sponsor : Merck & Co

                          Deal Size : $2,012.0 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : HS-20093 is a novel B7-H3-targeted ADC composed of a fully-humanized anti-B7-H3 monoclonal antibody covalently linked to TOPOi payload and being developed in China for small cell lung cancer.

                          Product Name : HS-20093

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          November 22, 2024

                          Lead Product(s) : HS-20093

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Under the agreement, GSK will obtain exclusive worldwide rights to progress development and commercialisation for HS-20093, a B7-H3 targeted antibody-drug conjugate (ADC) utilising a clinically validated topoisomerase inhibitor (TOPOi) payload, in advanc...

                          Product Name : HS-20093

                          Product Type : Other Large Molecule

                          Upfront Cash : $185.0 million

                          December 20, 2023

                          Lead Product(s) : HS-20093

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : GSK

                          Deal Size : $1,710.0 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Under the agreement, GSK will obtain rights to progress development and commercialisation for HS-20089, a B7-H4 targeted antibody-drug conjugate currently in phase I clinical trials in China, in ovarian and endometrial cancer.

                          Product Name : HS-20089

                          Product Type : Other Large Molecule

                          Upfront Cash : $85.0 million

                          October 20, 2023

                          Lead Product(s) : HS-20089

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : GSK

                          Deal Size : $1,570.0 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The results of the study demonstrate the superior safety and efficacy profile of Ameile (aumolertinib) in the first-line treatment of EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC.

                          Product Name : Ameile

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 31, 2022

                          Lead Product(s) : Aumolertinib Mesylate,Carboplatin,Pemetrexed

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC).

                          Product Name : Ameile

                          Product Type : Other Small Molecule

                          Upfront Cash : $100.0 million

                          July 23, 2020

                          Lead Product(s) : Aumolertinib Mesylate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : EQRx

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank